INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

LYELLyell Immunopharma, Inc.

CIK 0001806952

EDGAR filingsOpen in network
Disclosed transactions28
Buys / sells0 / 21
Max Insider Score37
Connections6with evidence

LYEL · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
AM
Aguirre Jarrad MattieuChief Medical Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$3,642
422 sh
Oct 12, 2026Oct 13, 2026
traded Oct 12, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Aguirre Jarrad MattieuChief Medical Officer · Sep 10, 2026
  • ← Insider ofevidence
    Shook DavidChief Medical Officer · Feb 11, 2026
  • ← Insider ofevidence
    Hill Stephen J.Chief Operating Officer · Nov 12, 2025
17
SD
Shook DavidChief Medical Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL
$6,350
500 sh
Sep 10, 2026
Sep 10, 2026
traded Sep 10, 2026
+0d
SEC FORM 4

Evidence

9
AM
Aguirre Jarrad MattieuChief Medical Officer
LYELLyell Immunopharma, Inc.
Grant or award
A—
47.5K sh
Sep 10, 2026Sep 10, 2026
traded Sep 10, 2026
+0dSEC FORM 4

Evidence

31
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$15K
989 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

31
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$23K
1,457 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

27
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$8,905
621 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

27
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$1,879
131 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

27
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$1,276
89 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

37
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$2,460
130 sh
May 11, 2026Jun 15, 2026
traded May 11, 2026
+35dSEC FORM 4

Evidence

37
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$1,684
89 sh
May 11, 2026Jun 15, 2026
traded May 11, 2026
+35dSEC FORM 4

Evidence

37
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$4,103
217 sh
May 11, 2026Jun 15, 2026
traded May 11, 2026
+35dSEC FORM 4

Evidence

25
SD
Shook DavidChief Medical Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$25K
1,977 sh
Jun 10, 2026Jun 11, 2026
traded Jun 10, 2026
+1dSEC FORM 4

Evidence

31
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$29K
1,236 sh
Feb 11, 2026Feb 12, 2026
traded Feb 11, 2026
+1dSEC FORM 4

Evidence

31
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$39K
1,671 sh
Feb 11, 2026Feb 12, 2026
traded Feb 11, 2026
+1dSEC FORM 4

Evidence

13
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Grant or award
A—
4,000 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

27
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$2,520
109 sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

27
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$3,399
147 sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

5
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Grant or award
A—
50.0K sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

13
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Grant or award
A—
4,000 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

5
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Grant or award
A—
65.0K sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

27
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$5,872
254 sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

17
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Grant or award
A—
8,750 sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

9
SD
Shook DavidChief Medical Officer
LYELLyell Immunopharma, Inc.
Grant or award
A—
50.0K sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

31
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$44K
1,136 sh
Dec 24, 2025Jan 6, 2026
traded Dec 24, 2025
+13dSEC FORM 4

Evidence

27
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$30K
936 sh
Dec 30, 2025Jan 6, 2026
traded Dec 30, 2025
+7dSEC FORM 4

Evidence

31
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$3,848
239 sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence

31
LK
Lee Gary K.Chief Scientific Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$2,230
138 sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence

31
HJ
Hill Stephen J.Chief Operating Officer
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$1,531
95 sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Bulis Veronica SanchezVP, Corporate Controller · Nov 12, 2025
  • ← Insider ofevidence
    Lee Gary K.Chief Scientific Officer · Nov 12, 2025